Precipio is a healthcare solutions company focused on cancer diagnostics. Co.'s IV-Cell is a proprietary cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables simultaneous culturing of four hematopoietic cell lineages. IV-Cell allows the laboratory technician to select any of the four lineages during the culturing process for analysis. In addition, Co. initially developed HemeScreen technology to target Myeloproliferative Neoplasms but it has enhanced HemeScreen into a suite of genetic diagnostic panels. Co.'s ICE COLD PCR is a proprietary specimen enrichment technology that increases the sensitivity of molecular based tests. The PRPO stock yearly return is shown above.
The yearly return on the PRPO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PRPO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|